IndiTreat®

Kontakt
2cureX A/S
Fruebjergvej 3, 2100 Copenhagen

Tel.: +45 22115399 | **E-mail:** info@2curex.com

www.2cureX.com

Challenges in cancer treatment

In the drug therapy of solid tumors usually cancer drugs are used, whose effectiveness is measured in clinical trials that included a large group of patients. It is however known that cancer patients individually respond very different to a therapy. Cancer Tumors of INDIVIDUAL patients often turn out to be resistant to therapies to which other patients respond. The exact cause of these different responses is unknown. It is believed that resistances are strongly related to the structure and cellular composition of the individual tumor. With the IndiTreat® test it is possible to predict how well the tumor of an individual patient will react before treatment (pre-treatment) to various cancer drugs and their combination and which will have no effect.

The IndiTreat® test

The cell based, functional IndiTreat® procedure was developed for colorectal carcinoma (colon cancer) and assists the treating physician in choosing the most effective drug Therapy for the patient. In order to perform the IndiTreat® test a biopsy taken from tumor tissue. This tumor sample of living tumor cells will be collected in a 2cureX transport container and shipped within 24 hours by courier to the nearest 2cureX laboratory. From the collected tumor tissue the 2cureX lab will produce three-dimensional microtumors consisting of approximately 300 cells. In own Studies and numerous scientific publications, it has been shown that this approach preserves the microenvironment, in other words the structural composition and the specific characteristics of the primary tumor remain. Then, over a period of about a week, the growth of the Microtumors are observed in the presence and absence of anticancer drugs. The 3D microtumors are considered sensitive or resistant to the therapies that inhibit growth - or not. In clinical studies, it has been shown that the response of the cultured tumors to the medication is comparable to the patient tumors. Through the pre-therapeutic identification of an effective therapy against the individual tumor, unnecessary side effects and disease progression could be minimized.

Differentiation IndiTreat® to DNA tests

There are several approaches to evaluate a cancer patient's response to therapy (Chemosensitivity). The main advantage of IndiTreat® over genomic and proteomic methods is the general applicability of IndiTreat®. Only about 10% of cancer patients carry a mutation or a protein pattern for which an appropriate drug therapy is available. On the other hand, there are many anticancer drugs whose effectiveness are not related to a mutation. Finally, it should be emphasized that genomic Approaches usually only predict the response to monotherapies. For frequently used Drug combinations DNA tests are not very suitable. In contrast, the IndiTreat® test is independent of any mutations and protein patterns. Instead, the effect of medication on the Function and growth of the microtumors measured.

About 2cureX

The IndiTreat® test has been used since 2006 on patient samples from more than 1000 patients, 2cureX A/S originates from Copenhagen, Denmark and developed the IndiTreat® test in close cooperation with several clinics. In 2015 a German subsidiary was established in Hamburg (2cureX GmbH).

Refund IndiTreat®

Reimbursement of cancer drugs differ from country to country, in general the costs incurred in the context of normal cancer therapy are paid by the general health insurance of the Patients. Unfortunately, IndiTreat® is currently not a general hospital service and will not yet recognized by the statutory health insurance. For more information regarding the availability of IndiTreat in your area please consult your physician or contact to 2cureX.



1. Agreement
The physician clarifies the benefits and risks of an in vitro chemosensitivity test related to the IndiTreat® test for the patient. When there is an agreement to perform the IndiTreat® test, the consent as well as the Test-Order form will be signed.

2. Tissue sampling and shipping
During an operative procedure, tumor tissue will be collected. The tumor sample will be collected in a special medium to preserve the tumor tissue and will be transported in a 2cureX transport box together with the needed documentation to a 2cureX lab within 24 hours.

3. Processing the tumor sample
In the first part of the IndiTreat® test the 2cureX lab will create approx. 1500 3D micro tumors from the collected tumor tissue that will be preserved and cultured in the 2cureX laboratory.

4. Conduct IndiTreat® test
The 3D microtumors will be treated with a panel of different individual cancer drugs or drug combinations in order to measure growth or decline of the microtumors based on the drug treatment.

5. Evaluation and report
The microtumors will be classified sensitive or resistant against the drugs that inhibit growth - or not. The physician receives from 2cureX a report on how the micro-tumors of the individual patient react on the different treatment regimes.

6. Individualized therapy choice
Based on the IndiTreat® result and under consideration of all available information from the patients' medical background the physician chooses the one for the most appropriate drug therapy for the patient.

2cureX AB

Info@2curex.com
www.2curex.com

Market: Nasdaq First North, Stockholm
Ticker: 2CUREX.ST

Twitter: @2cureX

LinkedIn: 2cureX